Core Viewpoint - The article discusses the legal developments regarding Lingda Co., Ltd. (300125) related to false statements and investor compensation claims, highlighting that some investors have already won their cases in the first instance [1][3]. Group 1: Legal Violations - Lingda Co., Ltd. failed to disclose external guarantee matters, with two guarantees totaling 80 million yuan not reported in the 2023 annual report, representing 19.42% of the audited net assets for that period [4][5]. - The company also did not disclose related party fund occupation, with a cumulative amount of 65.6 million yuan over 12 months, which is 9.95% of the latest audited net assets. Specific undisclosed fund occupations amounted to 50 million yuan, representing 12.13% of the audited net assets [2][5]. Group 2: Investor Compensation - Investors who purchased Lingda Co., Ltd. shares between July 5, 2023, and April 27, 2024, and sold or continued to hold the shares after April 27, 2024, are eligible to initiate compensation claims [3][6]. - The law firm representing investors, led by attorney Xu Feng, continues to accept claims from other investors and is actively pursuing further legal actions [1][3].

Regulatory Actions - Multiple listed companies are facing regulatory scrutiny for information disclosure violations, with Tianpu Co. and Xiangrikui being investigated, while Jushi Chemical received a pre-penalty notice [1][2][3] - ST Huilun and Langjin Technology have received administrative penalty decisions for various violations, including failure to disclose fund occupation and false financial reporting [4] Risk Warning Adjustments - New Asia Process and Yishite successfully removed risk warnings and changed their stock names, indicating improved market recognition after rectification [5] - ST Ningke has also had its delisting risk warning lifted, reflecting the resolution of previous issues related to timely information disclosure [5] Investor Litigation - Investors represented by the Xie Liang lawyer team have won a first-instance judgment against ST Renzihang for securities fraud, allowing eligible investors to register for compensation [6] - The case revealed that ST Renzihang had inflated revenue and profits through fictitious transactions, leading to significant financial misstatements in their reports [6] Compensation Conditions - Preliminary conditions for investor compensation have been outlined, specifying the time frames and stock purchase conditions for various companies involved in the regulatory actions [7] - Investors who meet these conditions can register their losses through designated platforms for potential legal action [8]

Core Viewpoint - The Shanghai Stock Exchange issued a regulatory warning to China Electronics Technology Group Corporation Digital Technology Co., Ltd. (referred to as "CETC Digital") due to inaccurate and incomplete information disclosure regarding its commercial aerospace and AI business, which misled investors [1][4]. Group 1: Regulatory Actions - CETC Digital's former board secretary, Hou Zhiping, received a regulatory warning for failing to disclose product progress and scale accurately, and for not adequately warning about risks until regulatory intervention occurred [1][4]. - The regulatory warning led to a significant drop in CETC Digital's stock price on January 13, 2026, affecting investors who bought shares at higher prices [1][4]. Group 2: Investor Compensation - Investors who purchased CETC Digital shares between January 5, 2026, and January 12, 2026, and still hold them, may voluntarily register for compensation through the "Sina Investor Rights Protection Platform," regardless of whether they sold their shares after January 13, 2026 [2][5]. - Legal counsel from Shanghai Xinben Law Firm indicated that investors suffering losses due to false disclosures or misleading statements may file lawsuits for compensation under relevant securities laws [1][4].

Core Viewpoint - The article discusses ongoing legal actions against Guandian Defense (688287) and Hainan Huatie (603300) for alleged false statements and incomplete disclosures, leading to investor claims for compensation. Group 1: Guandian Defense - Guandian Defense is facing investor claims due to false statements and incomplete disclosures regarding non-operating fund occupation and related party transactions from 2022 to 2024 [5][6] - The law firm representing investors has submitted a claim to the Shanghai Financial Court, which has already accepted the case and is awaiting further arrangements [1][4] - Investors who purchased Guandian Defense stock between May 25, 2022, and April 30, 2024, are eligible to initiate claims [2][7] Group 2: Hainan Huatie - Hainan Huatie is also under scrutiny for failing to disclose significant contract details and changes in a timely manner, particularly regarding a contract worth 3.69 billion yuan [7][8] - The company did not adequately disclose critical terms of the "Computing Power Service Agreement," which could impact the contract's execution [8] - Investors who bought Hainan Huatie stock between March 5, 2025, and October 1, 2025, can also file claims [9]

Core Viewpoint - Zhejiang Sunflower (stock code: 300111) has received a notice from the China Securities Regulatory Commission (CSRC) regarding potential administrative penalties for suspected violations of information disclosure laws [1] Group 1: Company Announcement - The company has stated that it has not yet received the final penalty decision from the CSRC, and the outcome will depend on the formal decision issued by the CSRC [1] - According to the Securities Law and relevant judicial interpretations, if a listed company causes investor losses due to false statements, it must bear civil compensation responsibilities [1] Group 2: Investor Compensation - Preliminary compensation scope includes investors who purchased Sunflower stock between its listing and before the market close on January 15, 2026, and still hold the stock at that time [2] - Investors are required to prepare specific materials, including original transaction statements stamped by the brokerage, copies of their ID cards, and a securities account information query issued by the brokerage [3][4] Group 3: Legal Perspective - The preliminary registration conditions for compensation are based on publicly available information and relevant laws, and may be adjusted as regulatory investigations and judicial processes progress [5]

Core Viewpoint - The company, Zhejiang Sunflower Health Technology Co., Ltd., has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into alleged violations of information disclosure laws, leading to a formal case being opened against the company [1][2][3]. Group 1: Investigation Details - The CSRC's investigation is prompted by market doubts regarding the actual production capacity and business model of the company's restructuring targets, which are suspected of containing misleading statements [3][4]. - The Zhejiang Securities Regulatory Bureau has initiated a verification process and will handle the case based on a comprehensive investigation to maintain order in the mergers and acquisitions market [3]. Group 2: Termination of Restructuring Plans - Concurrently, the company announced the termination of its plans to issue shares and pay cash for the acquisition of 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., as well as to raise supporting funds through a share issuance [2][4]. - The termination is due to the company's non-compliance with conditions for issuing shares to purchase assets following the receipt of the CSRC's notice [4]. Group 3: Investor Implications - Legal experts indicate that investors who purchased shares between September 22, 2025, and January 14, 2026, and sold or held them after January 15, 2026, may be eligible for compensation due to the company's situation [2][4].

Core Viewpoint - The Zhejiang Securities Regulatory Bureau has imposed administrative penalties on Zhongxinghua Accounting Firm for issuing false audit reports for Yinjian Technology's financial statements for 2021 and 2022, leading to potential legal actions from investors [1][5]. Group 1: Violations by Zhongxinghua Accounting Firm - Zhongxinghua Accounting Firm's audit reports for Yinjian Technology for the years 2021 and 2022 contained false records [1][5]. - The firm failed to exercise due diligence during the audit of Yinjian Technology's financial statements for 2021 and 2022 [1][5]. Group 2: Violations by Yinjian Technology - Yinjian Technology did not disclose related party non-operating fund occupation as required, resulting in false records in the 2023 annual report and the 2024 semi-annual report [5][6]. - The company failed to disclose related guarantees, leading to significant omissions in annual reports from 2018 to 2023 [6]. - Financial reports from 2021 to the third quarter of 2023 contained false records: - In 2021, due to delays in a photovoltaic project, Yinjian Technology inflated its operating income by 16.4571 million and total profit by 16.2102 million, accounting for 0.82% and 15.08% of the reported amounts, respectively [7]. - In 2022, the company inflated its operating income by 57.2741 million and total profit by 14.9252 million, representing 3.55% and 19.97% of the reported amounts, respectively [7]. - From January to September 2023, Yinjian Technology inflated its operating income and total profit through fictitious project businesses and income [7]. Group 3: Legal Actions and Investor Claims - Attorney Xu Feng from Shanghai Jiucheng Law Firm is representing investors in claims against Yinjian Technology and plans to include Zhongxinghua Accounting Firm as a co-defendant, seeking joint liability for compensation [1][5]. - Investors who purchased Yinjian Technology stock between April 19, 2019, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024, may initiate claims [8].

Core Viewpoint - The article discusses the ongoing legal actions against Zhongqingbao (300052) due to violations related to false financial reporting and failure to disclose significant legal issues involving its actual controller [1][4]. Group 1: Legal Violations - Zhongqingbao's subsidiary, Shenzhen Baoteng Internet Technology Co., Ltd., engaged in fictitious transactions with several companies, leading to inflated revenue and costs from 2019 to 2021 [2][5]. - The inflated figures include: - 2019: Revenue inflated by 33.61 million yuan (7.17% of reported revenue), costs inflated by 25.28 million yuan, and profit inflated by 8.33 million yuan (14.96% of reported profit) [2][5]. - 2020: Revenue inflated by 28.09 million yuan (9.56%), costs inflated by 21.11 million yuan, and profit inflated by 6.98 million yuan (5.45%) [2][5]. - 2021: Revenue inflated by 17.88 million yuan (5.03%), costs inflated by 25.09 million yuan, and profit reduced by 7.21 million yuan (13.17%) [2][5]. Group 2: Disclosure Failures - The actual controller of Zhongqingbao, Zhang Yunxia, was criminally detained on December 29, 2023, for failing to execute a judgment, but this was not disclosed in a timely manner to avoid impacting financing [3][6]. - The company only disclosed this information on July 26, 2024, after being pressured to do so [3][6]. Group 3: Investor Compensation - Investors who purchased Zhongqingbao shares between March 27, 2020, and April 27, 2023, or between April 23, 2024, and July 29, 2024, may still initiate claims for compensation [3][6].

2026年1月12日，上海久诚律师事务所股票索赔律师许峰代理的农尚环境（维权）（300536）投资者索 赔案已向武汉市中级人民法院提交立案，目前正在等待法院的下一步安排。律师团队还在继续推进后续 案件的立案工作，还在继续接受其他投资者的索赔委托。需要提示的是，农尚环境投资者索赔案前期已 有投资者胜诉先例。（许峰律师专栏） 2024年11月5日，农尚环境发布关于收到湖北证监局警示函的公告，经查，农尚环境存在以下违规事 实：2024年4月29日，农尚环境披露《2023年年度报告》显示，2023年度营业收入为7，142.74万元，归 属于上市公司股东的净利润为-2，976.66万元，因2023年经审计的净利润为负值且营业收入低于1亿 元，公司股票交易自2024年4月30日被实施退市风险警示。农尚环境公司未按规定在2023年会计年度结 束后一个月内披露2023年度业绩预告、也未对公司股票交易可能被实施退市风险警示的风险予以提示。 专门从事股票索赔法律事务的上海久诚律师事务所主任许峰律师认为，在2024年2月1日到2024年4 月29日之间买入农尚环境股票，并且在2024年4月29日后卖出或继续持有股票的投资者，目前还 ...

Core Viewpoint - Long Pharmaceutical Holdings (300391) is facing significant legal and financial challenges due to false financial reporting and potential forced delisting from the Shenzhen Stock Exchange, which has led to investor claims for compensation [2][4]. Group 1: Legal Issues - The Wuhan Intermediate People's Court has accepted batch claims from investors against Long Pharmaceutical Holdings, with ongoing efforts to accept more claims [1][3]. - There have been precedents of successful claims by investors against Long Pharmaceutical Holdings, indicating a potential for further compensation opportunities [1][3]. Group 2: Financial Misreporting - The company has been found to have inflated its revenue and profit figures in its annual reports for 2021, 2022, and 2023, with inflated revenues of 215.32 million, 283.74 million, and 233.63 million respectively, representing 9.12%, 17.57%, and 19.51% of reported revenues [2][4]. - The inflated profit totals were 56.40 million, 63.38 million, and 43.71 million for the same years, accounting for 35.62%, 88.23%, and 6.42% of reported profits [2][4]. - The company may face forced delisting due to continuous false reporting of financial metrics over three years, as per the Shenzhen Stock Exchange regulations [2][4]. Group 3: Financial Health - As of the latest report, Long Pharmaceutical Holdings has a significant fund occupation amounting to 179.66 million, which is 92.08% of its latest audited net assets [3][5]. - The company plans to resolve the fund occupation through the transfer of debts with related parties [3][5].